PFS in patients receiving SOC cilta-cel based on patient and treatment characteristics. (A) High-risk cytogenetics. (B) Extramedullary disease. (C) Plasma cell leukemia. (D) ECOG performance status (PS). (E) Age (≥70 years vs <70 years). (F) Lymphodepletion (LD) chemotherapy (Flu/Cy and others).